UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.
You may also be interested in...
UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures
A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.
Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.
Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.